Low-dose immunogenic chemotherapeutics promotes immune checkpoint blockade in microsatellite stability colon cancer

Low-dose immunogenic chemotherapeutics promotes immune checkpoint blockade in microsatellite stability colon cancer

More than 85% of colorectal cancer (CRC) patients, who are with microsatellite stability (MSS), are resistant to immune checkpoint blockade (ICB) treatment. To overcome this resistance, combination therapy with chemotherapy is the most common choice. However, many CRC patients do not benefit more fr...

Full description

Bibliographic Details
Main Authors: Yuhang Fang, Haoyu Sun, Xinghui Xiao, Maoxing Tang, Zhigang Tian, Haiming Wei, Rui Sun, Xiaodong Zheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
TIGIT blockade
immunogenic chemotherapeutics
immunogenic cell death
colon cancer
microsatellite stability
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1040256/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1040256/full

Similar Items